These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 26505121)

  • 1. Novel pH-sensitive multifunctional envelope-type nanodevice for siRNA-based treatments for chronic HBV infection.
    Yamamoto N; Sato Y; Munakata T; Kakuni M; Tateno C; Sanada T; Hirata Y; Murakami S; Tanaka Y; Chayama K; Hatakeyama H; Hyodo M; Harashima H; Kohara M
    J Hepatol; 2016 Mar; 64(3):547-55. PubMed ID: 26505121
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Knockdown of Virus Antigen Expression Increases Therapeutic Vaccine Efficacy in High-Titer Hepatitis B Virus Carrier Mice.
    Michler T; Kosinska AD; Festag J; Bunse T; Su J; Ringelhan M; Imhof H; Grimm D; Steiger K; Mogler C; Heikenwalder M; Michel ML; Guzman CA; Milstein S; Sepp-Lorenzino L; Knolle P; Protzer U
    Gastroenterology; 2020 May; 158(6):1762-1775.e9. PubMed ID: 32001321
    [TBL] [Abstract][Full Text] [Related]  

  • 3. EsiRNAs inhibit Hepatitis B virus replication in mice model more efficiently than synthesized siRNAs.
    Xuan B; Qian Z; Hong J; Huang W
    Virus Res; 2006 Jun; 118(1-2):150-5. PubMed ID: 16423421
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combination of small interfering RNAs mediates greater inhibition of human hepatitis B virus replication and antigen expression.
    Chen Z; Xu ZF; Ye JJ; Yao HP; Zheng S; Ding JY
    J Zhejiang Univ Sci B; 2005 Apr; 6(4):236-41. PubMed ID: 15754419
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 5'-triphosphate-siRNA activates RIG-I-dependent type I interferon production and enhances inhibition of hepatitis B virus replication in HepG2.2.15 cells.
    Chen X; Qian Y; Yan F; Tu J; Yang X; Xing Y; Chen Z
    Eur J Pharmacol; 2013 Dec; 721(1-3):86-95. PubMed ID: 24099962
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibitory effect of the combination of CpG-induced cytokines with lamivudine against hepatitis B virus replication in vitro.
    Vincent IE; Lucifora J; Durantel D; Hantz O; Chemin I; Zoulim F; Trepo C
    Antivir Ther; 2009; 14(1):131-5. PubMed ID: 19320247
    [TBL] [Abstract][Full Text] [Related]  

  • 7. siRNA combinations mediate greater suppression of hepatitis B virus replication in mice.
    Li G; Fu L; Jiang J; Ping Y; Huang Y; Wang Y
    Cell Biochem Biophys; 2014 Jul; 69(3):641-7. PubMed ID: 24549857
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biological characteristics of the A1762T/G1764A mutant strain of hepatitis B virus in vivo.
    Leng XH; Chen EQ; Du LY; Bai L; Gong DY; Cheng X; Huang FJ; Tang H
    Mol Med Rep; 2015 Oct; 12(4):5141-8. PubMed ID: 26165271
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Activity of stabilized short interfering RNA in a mouse model of hepatitis B virus replication.
    Morrissey DV; Blanchard K; Shaw L; Jensen K; Lockridge JA; Dickinson B; McSwiggen JA; Vargeese C; Bowman K; Shaffer CS; Polisky BA; Zinnen S
    Hepatology; 2005 Jun; 41(6):1349-56. PubMed ID: 15880588
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combination therapy of siRNAs mediates greater suppression on hepatitis B virus cccDNA in HepG2.2.15 cell.
    Xin XM; Li GQ; Guan XR; Li D; Xu WZ; Jin YY; Gu HX
    Hepatogastroenterology; 2008; 55(88):2178-83. PubMed ID: 19260501
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use of RNA interference to modulate liver adenoma development in a murine model transgenic for hepatitis B virus.
    Chen CC; Chang CM; Sun CP; Yu CP; Wu PY; Jeng KS; Hu CP; Chen PJ; Wu JC; Shih CH; Gershwin ME; Tao MH
    Gene Ther; 2012 Jan; 19(1):25-33. PubMed ID: 21562593
    [TBL] [Abstract][Full Text] [Related]  

  • 12. RNA interference inhibits hepatitis B virus gene expression and replication in HepG2-N10 cells.
    Ren JL; Pan JS; Cheng T; Dong J; Lu YP; Huang SJ; Shi HX; Wang L; Lian YM
    Chin J Dig Dis; 2006; 7(4):230-6. PubMed ID: 17054586
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Optimal design and validation of antiviral siRNA for targeting hepatitis B virus.
    Fu J; Tang ZM; Gao X; Zhao F; Zhong H; Wen MR; Sun X; Song HF; Qian XH
    Acta Pharmacol Sin; 2008 Dec; 29(12):1522-8. PubMed ID: 19026173
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association Between Level of Hepatitis B Surface Antigen and Relapse After Entecavir Therapy for Chronic Hepatitis B Virus Infection.
    Chen CH; Hung CH; Hu TH; Wang JH; Lu SN; Su PF; Lee CM
    Clin Gastroenterol Hepatol; 2015 Nov; 13(11):1984-92.e1. PubMed ID: 26073492
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term follow-up of children with postnatal immunoprophylaxis failure who were infected with hepatitis B virus surface antigen gene mutant.
    Hsu HY; Chang MH; Ni YH; Jeng YM; Chiang CL; Chen HL; Wu JF; Chen PJ
    J Infect Dis; 2013 Apr; 207(7):1047-57. PubMed ID: 23300165
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prediction of response to entecavir therapy in patients with HBeAg-positive chronic hepatitis B based on on-treatment HBsAg, HBeAg and HBV DNA levels.
    Shin JW; Jung SW; Park BR; Kim CJ; Eum JB; Kim BG; Jeong ID; Bang SJ; Lee SH; Kim SR; Park NH
    J Viral Hepat; 2012 Oct; 19(10):724-31. PubMed ID: 22967104
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of replication of hepatitis B virus in transgenic mice following administration of hepatotropic lipoplexes containing guanidinopropyl-modified siRNAs.
    Marimani MD; Ely A; Buff MC; Bernhardt S; Engels JW; Scherman D; Escriou V; Arbuthnot P
    J Control Release; 2015 Jul; 209():198-206. PubMed ID: 25937322
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hepatitis B surface antigen: relation to hepatitis B replication parameters in HBeAg-negative chronic hepatitis B.
    Manesis EK; Papatheodoridis GV; Tiniakos DG; Hadziyannis ES; Agelopoulou OP; Syminelaki T; Papaioannou C; Nastos T; Karayiannis P
    J Hepatol; 2011 Jul; 55(1):61-8. PubMed ID: 21145875
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intrahepatic response markers in chronic hepatitis B patients treated with peginterferon alpha-2a and adefovir.
    Takkenberg B; Terpstra V; Zaaijer H; Weegink C; Dijkgraaf M; Jansen P; Beld M; Reesink H
    J Gastroenterol Hepatol; 2011 Oct; 26(10):1527-35. PubMed ID: 21557773
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of hepatitis B e antigen-suppressing mutations on the replication efficiency of entecavir-resistant hepatitis B virus strains.
    Amini-Bavil-Olyaee S; Herbers U; Luedde T; Trautwein C; Tacke F
    J Viral Hepat; 2011 Nov; 18(11):804-14. PubMed ID: 20887378
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.